Animal Models for SARS-CoV-2 and SARS-CoV-1 Pathogenesis, Transmission and Therapeutic Evaluation
Overview
Authors
Affiliations
There is a critical need to develop animal models to alleviate vaccine and drug development difficulties against zoonotic viral infections. The coronavirus family, which includes severe acute respiratory syndrome coronavirus 1 and severe acute respiratory syndrome coronavirus 2, crossed the species barrier and infected humans, causing a global outbreak in the 21 century. Because humans do not have pre-existing immunity against these viral infections and with ethics governing clinical trials, animal models are therefore being used in clinical studies to facilitate drug discovery and testing efficacy of vaccines. The ideal animal models should reflect the viral replication, clinical signs, and pathological responses observed in humans. Different animal species should be tested to establish an appropriate animal model to study the disease pathology, transmission and evaluation of novel vaccine and drug candidates to treat coronavirus disease 2019. In this context, the present review summarizes the recent progress in developing animal models for these two pathogenic viruses and highlights the utility of these models in studying SARS-associated coronavirus diseases.
Varghese A, Liu J, Liu B, Guo W, Dong F, Patterson T Molecules. 2025; 30(3).
PMID: 39942596 PMC: 11820935. DOI: 10.3390/molecules30030491.
Outcome of SARS-CoV-2 reinfection depends on genetic background in female mice.
Singh G, Diego J, Warang P, Park S, Chang L, Noureddine M Nat Commun. 2024; 15(1):10178.
PMID: 39580470 PMC: 11585546. DOI: 10.1038/s41467-024-54334-7.
Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models.
Zheng H, Song T, Zheng Y Zool Res. 2024; 45(4):747-766.
PMID: 38894519 PMC: 11298684. DOI: 10.24272/j.issn.2095-8137.2024.062.
Collins C, Longo D, Murphy W Front Immunol. 2024; 15:1345499.
PMID: 38469293 PMC: 10925677. DOI: 10.3389/fimmu.2024.1345499.
Cruz Cisneros M, Anderson E, Hampton B, Parotti B, Sarkar S, Taft-Benz S Vaccines (Basel). 2024; 12(1).
PMID: 38276675 PMC: 10821422. DOI: 10.3390/vaccines12010103.